Diversified Consumer Services
Company Overview of The University of Texas M. D. Anderson Cancer Center
The University of Texas M. D. Anderson Cancer Center is an educational institution that offers undergraduate and research programs to physicians, biomedical scientists, and other health-care professionals. The departments include behavioral medicine, biochemistry and molecular biology, cancer biology program, cancer genomics core laboratory, molecular and cellular oncology, molecular genetics, molecular hematology and therapy, molecular therapeutics, and molecular pathology. The University of Texas M. D. Anderson Cancer Center was founded in 1941 as Texas State Cancer Hospital and the Division of Cancer Research and changed its name to M. D. Anderson Hospital for Cancer Research of The Unive...
1515 Holcombe Boulevard
Houston, TX 77030
Founded in 1989
Key Executives for The University of Texas M. D. Anderson Cancer Center
Executive Vice President and Physician-In-Chief
Chairman of Department of Health Disparities Research
Vice President and Head of the Division of Pharmacy
Compensation as of Fiscal Year 2014.
The University of Texas M. D. Anderson Cancer Center Key Developments
The University of Texas M. D. Anderson Cancer Center Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 through Nov-13-2014
Oct 27 14
The University of Texas M. D. Anderson Cancer Center Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 through Nov-13-2014. Venue: Apella, 450 East 29th Street, New York, New York, United States. Presentation Date & Speakers: Nov-12-2014, Jennifer Wheler. Nov-13-2014, Jennifer Wheler.
Bristol-Myers Squibb Company and MD Anderson Cancer Center of the University of Texas Announce Immuno-Oncology Partnership
Oct 8 14
Bristol-Myers Squibb and the MD Anderson Cancer Centre of the University of Texas have announced their immuno-oncology collaboration that will focus on advancement of novel therapies for the treatment of acute or chronic leukaemia and other haematologic malignancies. The clinical research partnership will include programmed cell death protein 1 (PD-1) inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab), as well as three undisclosed early-stage immuno-oncology candidates in BMS's pipeline. Up to 10 Phase I and Phase II clinical trials will be launched and conducted by the centre, investigating several monotherapy and combination regimens to treat acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndrome, and myelofibrosis. The two partners will determine if additional clinical trials will be launched at a later time.
Biocept Expands Collaboration with MD Anderson Cancer Center
Oct 7 14
Biocept, Inc. announced the furthering of its collaboration with The University of Texas MD Anderson Cancer Center regarding studies focused on patients diagnosed with ovarian cancer. The continuation of this collaboration follows the recent findings from an MD Anderson mouse model study published in the peer-reviewed medical journal, Cancer Cell in which Biocept's OncoCEE testing was utilized. The Company's OncoCEE microfluidic device captures CTCs and then evaluates the genomic marker, HER3 (human epidermal growth factor receptor 3), for expression on ovarian cancer cells in order to better understand alternative routes of metastasis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|